Cytori to Present at Regen Med Investor Day 2013 on April 17

  Cytori to Present at Regen Med Investor Day 2013 on April 17

Business Wire

SAN DIEGO -- April 10, 2013

Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today that President Marc
Hedrick, MD will present at the 2013 Regen Med Investor Day to be held
Wednesday, April 17, 2013 in New York City.

In addition to the corporate presentation, Dr. Hedrick will participate on the
“Clinical Outlooks in Cardiovascular Disease” panel, alongside Ronnda Bartel,
PhD of Aastrom Biosciences, Silviu Itescu, MBBS of Mesoblast Limited, Linda
Marban, PhD of Capricor and Leslie Miller, MD of the University of South
Florida Heart Institute.

Specific details for both events are as follows:

                             Clinical Outlooks in                Cytori
        Event:    Cardiovascular Disease Panel     Therapeutics
                Time:        9:00 AM EST                         1:00 PM EST

Organized by the Alliance for Regenerative Medicine (ARM) in partnership with
leading financial firms Burrill & Company, Maxim Group and Piper Jaffray, this
flagship event features 16 of the regenerative medicine field’s leading small-
and mid-cap companies. In addition, there will be disease indication-focused
discussions between key opinion leaders, top analysts and senior executives
from the sector and keynote-style talks by Jeff Jonas, President of Shire
Regenerative Medicine and Kieran Murphy, President and CEO, GE Healthcare Life

A live video webcast of the panels and company presentations will be available
at: and will also be published on ARM’s
website shortly after the event.

Attendance at this event is for credentialed investors and members of the
media only. If you are interested in attending, please contact Laura Parsons

About Cytori

Cytori Therapeutics is developing cell therapies based on autologous
adipose-derived regenerative cells (ADRCs) to treat cardiovascular disease and
other medical conditions. Our scientific data suggest ADRCs improve blood
flow, moderate the inflammatory response and keep tissue at risk of dying
alive. As a result, we believe these cells can be applied across multiple
"ischemic" conditions. These therapies are made available to the physician and
patient at the point-of-care by Cytori's proprietary technologies and
products, including the Celution® System product family.


Cytori Therapeutics
Megan McCormick
Press spacebar to pause and continue. Press esc to stop.